BioinvestGPT

BioinvestGPT ApS · Research use only

NCT03377491 (NovoTTF-200T in Pancreatic Cancer): BVCT ex-ante prediction vs. reported outcome

On 21 Aug 2024, BioinvestGPT's BVCT predicted technical failure and commercial partial success for this trial. The 2 Dec 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant (PFS data pending) and commercially sufficient (weakly superior OS).

Clinical Trial

NCTID
NCT03377491
Acronym
PANOVA-3
Drug Name
NovoTTF-200T
Drug MoA
a device delivering low-intensity; wave-like; alternating electric fields to tumor sites
Drug Modality
medical device
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Pancreatic Cancer
Human Patients
571
Sponsor
Novocure
Phase
Phase 3

Prediction of , index 985

Prospective Prediction
Prediction Index
985
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in OS)
Technical Prediction
FAILURE (statistically maybe significant yet very weak additive clinical benefit in PFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
103 days in advance
Readout Data Interpretation
TTFields + SoC achieved 16.20 months mOS compared with 14.16 months in patients who received SoC alone (p=0.039); no PFS data announced in topline readout (usually indicating unremarkable PFS data)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant (PFS data pending) and commercially sufficient (weakly superior OS)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Phase
Phase 3
Status
Completed
Enrollment
571
Lead sponsor
NovoCure Ltd.
Conditions
Pancreas Adenocarcinoma
Interventions
DEVICE: NovoTTF-200T; DRUG: Gemcitabine; DRUG: nab paclitaxel
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2018-05-10
Primary completion
2024-10-16
Completion
2024-10-16
Results first posted
2026-01-21
Primary outcomes
  • Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone (From randomization until death from any cause or last known alive.)

NCT03377491 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials